The tussle over the cost of the Sovaldi hepatitis C medication may prevent yet another segment of the population from being treated – people are enrolled in opioid treatment programs.. Although the drug has shown evidence of curing nine of 10 sufferers and the product labeling does not suggest Sovaldi is not safe for these patients, payers are balking at covering the medicine for people with a history of a substance use disorder.